Please use this identifier to cite or link to this item:
https://doi.org/10.1007/s11523-022-00886-x
Title: | Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors | Authors: | Choo, Joan RE Jan, Yi-Hua Ow, Samuel GW Wong, Andrea Lee, Matilda Xinwei Ngoi, Natalie Yadav, Kritika Lim, Joline SJ Lim, Siew Eng Chan, Ching Wan Hartman, Mikael Tang, Siau Wei Goh, Boon Cher Tan, Hon Lyn Chong, Wan Qin Yvonne, Ang Li En Chan, Gloria HJ Chen, Shu-Jen Tan, Kien Thiam Lee, Soo Chin |
Keywords: | Science & Technology Life Sciences & Biomedicine Oncology ESR1 MUTATIONS HETEROGENEITY RESISTANCE LANDSCAPE VEGF |
Issue Date: | 14-Jun-2022 | Publisher: | SPRINGER | Citation: | Choo, Joan RE, Jan, Yi-Hua, Ow, Samuel GW, Wong, Andrea, Lee, Matilda Xinwei, Ngoi, Natalie, Yadav, Kritika, Lim, Joline SJ, Lim, Siew Eng, Chan, Ching Wan, Hartman, Mikael, Tang, Siau Wei, Goh, Boon Cher, Tan, Hon Lyn, Chong, Wan Qin, Yvonne, Ang Li En, Chan, Gloria HJ, Chen, Shu-Jen, Tan, Kien Thiam, Lee, Soo Chin (2022-06-14). Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. TARGETED ONCOLOGY 17 (3) : 355-368. ScholarBank@NUS Repository. https://doi.org/10.1007/s11523-022-00886-x | Abstract: | Background: Breast cancers are heterogeneous with variable clinical courses and treatment responses. Objective: We sought to evaluate dynamic changes in the molecular landscape of HER2-negative tumors treated with chemotherapy and anti-angiogenic agents. Patients and Methods: Newly diagnosed HER2-negative breast cancer patients received low-dose sunitinib or bevacizumab prior to four 2-weekly cycles of dose-dense doxorubicin and cyclophosphamide. Tumor biopsies were obtained at baseline, after 2 weeks and after 8 weeks of chemotherapy. Next-generation sequencing was performed to assess for single nucleotide variants (SNVs) and copy number alterations (CNAs) of 440 cancer-related genes (ACTOnco®). Observed genomic changes were correlated with the Miller-Payne histological response to treatment. Results: Thirty-four patients received sunitinib and 18 received bevacizumab. In total, 77% were hormone receptor positive (HER2−/HR+) and 23% were triple negative breast cancers (TNBC). New therapy-induced mutations were infrequent, occurring only in 13%, and appeared early after a single cycle of treatment. Seventy-two percent developed changes in the variant allele frequency (VAF) of pathogenic SNVs; the majority (51%) of these changes occurred early at 2 weeks and were sustained for 8 weeks. Changes in VAF of SNVs were most commonly seen in the PI3K/mTOR/AKT pathway; 13% developed changes in pathogenic mutations, which potentially confer sensitivity to PIK3CA inhibitors. Tumors with poor Miller-Payne response to treatment were less likely to experience changes in VAF of SNVs compared with those with good response (50% [7/14] vs 15% [4/24] had no changes observed at any timepoint, p = 0.029). Conclusions: Serial molecular profiling identifies early therapy-induced genomic alterations, which may guide future selection of targeted therapies in breast cancer patients who progress after standard chemotherapy. Clinical trial registration: ClinicalTrials.gov: NCT02790580 (first posted June 6, 2016). | Source Title: | TARGETED ONCOLOGY | URI: | https://scholarbank.nus.edu.sg/handle/10635/237399 | ISSN: | 1776-2596 1776-260X |
DOI: | 10.1007/s11523-022-00886-x |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Ang.pdf | 2.16 MB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.